Title: Tutti Toot Trumpet. Development of new module measuring breathing rate, depth, pattern, quality, assisting treatment of children with Breathing Pattern Disorders, enabling complex breathing retraining interventions, delivered through play/gaming.
Funder: Department of Health and Social Care

Abstract: Tutti Toot Trumpet (TTT) is a novel digital, medical, musical device providing improved Airway Clearance Treatment (ACT) compliance/technique, real-time Positive Expiratory Pressure (PEP) measurements for children with chronic lung diseases. The development of a new TTT module to also measure Peak Flow Expiratory Rate (PEFR), breathing rate, depth, pattern and quality will assist treatment of children with Breathing Pattern Disorders (BPD) and asthma, enabling complex interventions to be delivered through play and gaming. Developing the TTT to provide biofeedback for breathing pattern retraining interventions will assist teaching/learning of complex breathing rhythms. This would offer for the first time, a device supporting the treatment of ACT/BPD and PEFR measurements, for primary school-aged children with asthma. Tutti Toot & Imperial College will investigate whether TTT improves adherence and engagement of children (5-11 years) with asthma in doing breathing exercises, the child s ability and self-efficacy in gaining correct breathing techniques whilst practicing at home, compared to standard care. The TTT measures PEP and tidal volumes over time, controlling musical games, whilst recording analytic data to an app. Functions: &bull; patient, parent, clinician connectivity, feedback of adherence and breathing performance. &bull; linking ACT/PEFR with learning music. &bull; gamifies therapy (similar to Guitar Hero ) connecting community of new users. &bull; Addresses poor ACT, PEFR, BPD techniques, by indicating optimum therapeutic pressures/flow. Tutti Toot ran PPI workshops (2021), streamlining their first user-testing pilot for children with cystic fibrosis. Patients said TTT was fun to use, effective clearing airway mucus, improved lung function tests. Breath data analysis (Professor Main UCL) suggested TTT produced breaths in keeping with gold standard oscillating ACT devices. The production/price point of TTT will be competitive. The cost of current ACT devices are &pound;120 to &pound;240 annually. TTT will reach TRL 6, own all IP arising during the project. TTT IP is undergoing UKIPO examination and PCT. TTT has been identified as Class Im/IIa device (Regulatory/Clinical report Nov 2021) after conformity assessment, CE marking.

Lay abstract: Tutti Toot Trumpet (TTT) is a novel digital, medical, musical device providing improved Airway Clearance Treatment (ACT) compliance/technique, real-time Positive Expiratory Pressure (PEP) measurements for children with chronic lung diseases. The development of a new TTT module to also measure Peak Flow Expiratory Rate (PEFR), breathing rate, depth, pattern and quality will assist treatment of children with Breathing Pattern Disorders (BPD) and asthma, enabling complex interventions to be delivered through play and gaming. Developing the TTT to provide biofeedback for breathing pattern retraining interventions will assist teaching/learning of complex breathing rhythms. This would offer for the first time, a device supporting the treatment of ACT/BPD and PEFR measurements, for primary school-aged children with asthma. Tutti Toot & Imperial College will investigate whether TTT improves adherence and engagement of children (5-11 years) with asthma in doing breathing exercises, the child s ability and self-efficacy in gaining correct breathing techniques whilst practicing at home, compared to standard care. The TTT measures PEP and tidal volumes over time, controlling musical games, whilst recording analytic data to an app. Functions: &bull; patient, parent, clinician connectivity, feedback of adherence and breathing performance. &bull; linking ACT/PEFR with learning music. &bull; gamifies therapy (similar to Guitar Hero ) connecting community of new users. &bull; Addresses poor ACT, PEFR, BPD techniques, by indicating optimum therapeutic pressures/flow. Tutti Toot ran PPI workshops (2021), streamlining their first user-testing pilot for children with cystic fibrosis. Patients said TTT was fun to use, effective clearing airway mucus, improved lung function tests. Breath data analysis (Professor Main UCL) suggested TTT produced breaths in keeping with gold standard oscillating ACT devices. The production/price point of TTT will be competitive. The cost of current ACT devices are &pound;120 to &pound;240 annually. TTT will reach TRL 6, own all IP arising during the project. TTT IP is undergoing UKIPO examination and PCT. TTT has been identified as Class Im/IIa device (Regulatory/Clinical report Nov 2021) after conformity assessment, CE marking.

Research activity codes: 5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES
Health categories: RESPIRATORY